B-Cell Lymphoma
126
26
33
48
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
20 trials with published results (16%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
11.1%
14 terminated out of 126 trials
77.4%
-9.2% vs benchmark
3%
4 trials in Phase 3/4
42%
20 of 48 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 48 completed trials
Clinical Trials (126)
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Phase I Study of FXS0683 in the Treatment of Blood Tumors
Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.